{"title":"Transient refractory period in severe iodinated contrast media allergy: a case report.","authors":"Lara S Dungan, Fionnuala Cox","doi":"10.1186/s13223-025-00972-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypersensitivity reactions to iodinated contrast media (ICM) are rare but can be life-threatening. Management typically involves avoidance of the offending agent and the use of alternative imaging strategies. The phenomenon of a transient refractory period-wherein a patient does not exhibit an allergic response upon re-exposure to the allergen shortly after an initial reaction-has been proposed but is not well-documented in the context of ICM.</p><p><strong>Case presentation: </strong>We report the case of a 56-year-old woman who experienced an anaphylaxis associated cardiac arrest following administration of iopamidol 370 (Niopam 370) during a computed tomography pulmonary angiogram (CTPA). She was resuscitated, intubated, and stabilized with noradrenaline. Two hours later, she underwent a second CT scan using iopamidol 300 (Niopam 300) without any obvious immediate hypersensitivity reaction. Subsequent skin testing was positive for both Niopam 370 and Niopam 300, but negative for alternative agents - iodixanol (Visipaque) and iohexol (Omnipaque).</p><p><strong>Conclusions: </strong>This case suggests the presence of a transient refractory period following a severe hypersensitivity reaction to ICM, during which re-exposure to the allergen does not elicit an immediate response. Understanding this phenomenon could have significant implications for the management of urgent imaging needs in patients with known ICM hypersensitivity.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"43"},"PeriodicalIF":2.4000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490029/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy Asthma and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13223-025-00972-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Hypersensitivity reactions to iodinated contrast media (ICM) are rare but can be life-threatening. Management typically involves avoidance of the offending agent and the use of alternative imaging strategies. The phenomenon of a transient refractory period-wherein a patient does not exhibit an allergic response upon re-exposure to the allergen shortly after an initial reaction-has been proposed but is not well-documented in the context of ICM.
Case presentation: We report the case of a 56-year-old woman who experienced an anaphylaxis associated cardiac arrest following administration of iopamidol 370 (Niopam 370) during a computed tomography pulmonary angiogram (CTPA). She was resuscitated, intubated, and stabilized with noradrenaline. Two hours later, she underwent a second CT scan using iopamidol 300 (Niopam 300) without any obvious immediate hypersensitivity reaction. Subsequent skin testing was positive for both Niopam 370 and Niopam 300, but negative for alternative agents - iodixanol (Visipaque) and iohexol (Omnipaque).
Conclusions: This case suggests the presence of a transient refractory period following a severe hypersensitivity reaction to ICM, during which re-exposure to the allergen does not elicit an immediate response. Understanding this phenomenon could have significant implications for the management of urgent imaging needs in patients with known ICM hypersensitivity.
期刊介绍:
Allergy, Asthma & Clinical Immunology (AACI), the official journal of the Canadian Society of Allergy and Clinical Immunology (CSACI), is an open access journal that encompasses all aspects of diagnosis, epidemiology, prevention and treatment of allergic and immunologic disease.
By offering a high-visibility forum for new insights and discussions, AACI provides a platform for the dissemination of allergy and clinical immunology research and reviews amongst allergists, pulmonologists, immunologists and other physicians, healthcare workers, medical students and the public worldwide.
AACI reports on basic research and clinically applied studies in the following areas and other related topics: asthma and occupational lung disease, rhinoconjunctivitis and rhinosinusitis, drug hypersensitivity, allergic skin diseases, urticaria and angioedema, venom hypersensitivity, anaphylaxis and food allergy, immunotherapy, immune modulators and biologics, immune deficiency and autoimmunity, T cell and B cell functions, regulatory T cells, natural killer cells, mast cell and eosinophil functions, complement abnormalities.